{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:22:56Z","timestamp":1786123376723,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,7]]},"DOI":"10.7759\/cureus.114123","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:33:21Z","timestamp":1786113201000},"source":"Crossref","is-referenced-by-count":0,"title":["Potential Vitamin B6 Depletion During Carbidopa\/Levodopa Therapy in Parkinson's Disease: A Scoping Review of Direct Evidence"],"prefix":"10.7759","author":[{"given":"Patryk","family":"Sielaff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Lis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Paw\u0142asek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142  R","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Sucharski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Micha\u0142owicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patryk","family":"Cierpia\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Puziuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Miko\u0142ajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Staranowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Dziurzy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patryk","family":"Dziurzy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kie\u0142basiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Piwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Parkinson disease. (2023). Accessed: July 23, 2026: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/parkinson-disease."},{"key":"ref2","unstructured":"National Institute for Health and Care Excellence. Parkinson's disease in adults; NICE guideline NG71. (2017). Accessed: July 23, 2026: https:\/\/www.nice.org.uk\/guidance\/ng71\/chapter\/Recommendations."},{"key":"ref3","unstructured":"DailyMed. SINEMET\u2014carbidopa and levodopa tablet. (2026). Accessed: July 23, 2026: https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=9b17b028-964a-473c-823d-81423535bd66."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12688","article-title":"Levodopa-induced neuropathy: a systematic review","volume":"6","author":"Romagnolo A","year":"2019","unstructured":"Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L. Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract. 2019, 6:96-103. 10.1002\/mdc3.12688","journal-title":"Mov Disord Clin Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1021\/acscatal.5c00326","article-title":"\u03b1-Hydrazino acids inhibit pyridoxal phosphate-dependent decarboxylases via \u2018catalytically correct\u2019 ketoenamine tautomers: a special motif for chemical biology and drug discovery?","volume":"15","author":"Baine JM","year":"2025","unstructured":"Baine JM, Duhoo Y, Doukov T, et al.. \u03b1-Hydrazino acids inhibit pyridoxal phosphate-dependent decarboxylases via \u2018catalytically correct\u2019 ketoenamine tautomers: a special motif for chemical biology and drug discovery?. ACS Catal. 2025, 15:8204-18. 10.1021\/acscatal.5c00326","journal-title":"ACS Catal"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008x(74)90055-6","article-title":"Preclinical toxicological studies of carbidopa and combinations of carbidopa and levodopa","volume":"29","author":"Zwickey RE","year":"1974","unstructured":"Zwickey RE, Peck HM, Bagdon WJ, et al.. Preclinical toxicological studies of carbidopa and combinations of carbidopa and levodopa. Toxicol Appl Pharmacol. 1974, 29:181-95. 10.1016\/0041-008x(74)90055-6","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000055899.24594.8e","article-title":"Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status","volume":"60","author":"Miller JW","year":"2003","unstructured":"Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology. 2003, 60:1125-9. 10.1212\/01.wnl.0000055899.24594.8e","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.698","article-title":"Effects of levodopa\/carbidopa intestinal gel versus oral levodopa\/carbidopa on B vitamin levels and neuropathy","volume":"7","author":"Loens S","year":"2017","unstructured":"Loens S, Chorbadzhieva E, Kleimann A, Dressler D, Schrader C. Effects of levodopa\/carbidopa intestinal gel versus oral levodopa\/carbidopa on B vitamin levels and neuropathy. Brain Behav. 2017, 7:e00698. 10.1002\/brb3.698","journal-title":"Brain Behav"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000408","article-title":"Vitamin B6 deficiency in patients with Parkinson disease treated with levodopa\/carbidopa","volume":"43","author":"Rojo-Sebasti\u00e1n A","year":"2020","unstructured":"Rojo-Sebasti\u00e1n A, Gonz\u00e1lez-Robles C, Garc\u00eda de Y\u00e9benes J. Vitamin B6 deficiency in patients with Parkinson disease treated with levodopa\/carbidopa. Clin Neuropharmacol. 2020, 43:151-7. 10.1097\/WNF.0000000000000408","journal-title":"Clin Neuropharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27338","article-title":"Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease","volume":"33","author":"Fernandez HH","year":"2018","unstructured":"Fernandez HH, Boyd JT, Fung VS, et al.. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Mov Disord. 2018, 33:928-36. 10.1002\/mds.27338","journal-title":"Mov Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mds.70388","article-title":"Do we need to monitor B-vitamins and homocysteine during initiation of foslevodopa\/foscarbidopa therapy?","author":"Shaghaghi-Zadeh A","year":"2026","unstructured":"Shaghaghi-Zadeh A, H\u00f6llerhage M, Wegner F, et al.. Do we need to monitor B-vitamins and homocysteine during initiation of foslevodopa\/foscarbidopa therapy?. Mov Disord. 2026, 10.1002\/mds.70388","journal-title":"Mov Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70629","article-title":"Peripheral neuropathy during subcutaneous foslevodopa\/foscarbidopa infusion in Parkinson's disease: a case series","author":"Vial-Daragon L","year":"2026","unstructured":"Vial-Daragon L, Poncet-Megemont L, Derost P, Beal C, Debilly B, Marques A. Peripheral neuropathy during subcutaneous foslevodopa\/foscarbidopa infusion in Parkinson's disease: a case series. Mov Disord Clin Pract. 2026, 10.1002\/mdc3.70629","journal-title":"Mov Disord Clin Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009647","article-title":"Pearls and oy-sters: vitamin B(6) deficiency presenting with new-onset epilepsy and status epilepticus in a patient with Parkinson disease","volume":"94","author":"Modica JS","year":"2020","unstructured":"Modica JS, Bonno D, Lizarraga KJ. Pearls and oy-sters: vitamin B(6) deficiency presenting with new-onset epilepsy and status epilepticus in a patient with Parkinson disease. Neurology. 2020, 94:e2605-7. 10.1212\/WNL.0000000000009647","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-012-0856-1","article-title":"Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson's disease under Duodopa\u00ae therapy","volume":"120","author":"Skodda S","year":"2013","unstructured":"Skodda S, M\u00fcller T. Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson's disease under Duodopa\u00ae therapy. J Neural Transm (Vienna). 2013, 120:315-8. 10.1007\/s00702-012-0856-1","journal-title":"J Neural Transm (Vienna)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-011-0689-3","article-title":"Malnutritional neuropathy under intestinal levodopa infusion","volume":"119","author":"Klostermann F","year":"2012","unstructured":"Klostermann F, Jugel C, M\u00fcller T, Marzinzik F. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm (Vienna). 2012, 119:369-72. 10.1007\/s00702-011-0689-3","journal-title":"J Neural Transm (Vienna)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23342","article-title":"Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under Duodopa therapy","volume":"25","author":"Urban PP","year":"2010","unstructured":"Urban PP, Wellach I, Faiss S, Layer P, Rosenkranz T, Knop K, Weis J. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under Duodopa therapy. Mov Disord. 2010, 25:1748-52. 10.1002\/mds.23342","journal-title":"Mov Disord"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30297","article-title":"Subacute painful axonal polyneuropathy associated with foslevodopa\/foscarbidopa subcutaneous infusion in advanced Parkinson's disease","volume":"40","author":"Valli A","year":"2025","unstructured":"Valli A, Scheperjans F. Subacute painful axonal polyneuropathy associated with foslevodopa\/foscarbidopa subcutaneous infusion in advanced Parkinson's disease. Mov Disord. 2025, 40:2538-9. 10.1002\/mds.30297","journal-title":"Mov Disord"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omaf191","article-title":"Carbidopa\/levodopa induced severe vitamin B6 deficiency leading to symptomatic transfusion dependent microcytic anemia","volume":"2026","author":"Lee BK","year":"2026","unstructured":"Lee BK, Gastwirt JP. Carbidopa\/levodopa induced severe vitamin B6 deficiency leading to symptomatic transfusion dependent microcytic anemia. Oxf Med Case Reports. 2026, 2026:omaf191. 10.1093\/omcr\/omaf191","journal-title":"Oxf Med Case Reports"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9577-22","article-title":"Vitamin B6 deficiency anemia attributed to levodopa\/carbidopa intestinal gel therapy for Parkinson's disease: a diagnostic pitfall for myelodysplastic syndrome with ring sideroblasts","volume":"61","author":"Yasuda H","year":"2022","unstructured":"Yasuda H, Hatano T, Honda T, Tsutsui M, Hattori N, Ando M, Komatsu N. Vitamin B6 deficiency anemia attributed to levodopa\/carbidopa intestinal gel therapy for Parkinson's disease: a diagnostic pitfall for myelodysplastic syndrome with ring sideroblasts. Intern Med. 2022, 61:3719-22. 10.2169\/internalmedicine.9577-22","journal-title":"Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco AC","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al.. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018, 169:467-73. 10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"ref21","unstructured":"US Food and Drug Administration. FDA is requiring warning about vitamin B6 deficiency and associated seizures for drug products containing carbidopa\/levodopa. (2026). Accessed: July 21, 2026: https:\/\/www.fda.gov\/drugs\/drug-safety-communications\/fda-requiring-warning-about-vitamin-b6-deficiency-and-associated...."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1042\/cs0560089","article-title":"Niacin depletion in parkinsonian patients treated with L-dopa, benserazide and carbidopa","volume":"56","author":"Bender DA","year":"1979","unstructured":"Bender DA, Earl CJ, Lees AJ. Niacin depletion in parkinsonian patients treated with L-dopa, benserazide and carbidopa. Clin Sci (Lond). 1979, 56:89-93. 10.1042\/cs0560089","journal-title":"Clin Sci (Lond)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010023031403","article-title":"Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa","volume":"303","author":"Sternberg EM","year":"1980","unstructured":"Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980, 303:782-7. 10.1056\/NEJM198010023031403","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1590\/s0100-879x2003001000019","article-title":"High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients","volume":"36","author":"Coimbra CG","year":"2003","unstructured":"Coimbra CG, Junqueira VB. High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients. Braz J Med Biol Res. 2003, 36:1409-17. 10.1590\/s0100-879x2003001000019","journal-title":"Braz J Med Biol Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1174","article-title":"Decreased hepatic enzymes reflect the decreased vitamin B6 levels in Parkinson's disease patients","volume":"12","author":"Ikenaka K","year":"2024","unstructured":"Ikenaka K, Kajiyama Y, Aguirre C, et al.. Decreased hepatic enzymes reflect the decreased vitamin B6 levels in Parkinson's disease patients. Pharmacol Res Perspect. 2024, 12:e1174. 10.1002\/prp2.1174","journal-title":"Pharmacol Res Perspect"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-026-03161-9","article-title":"Impact of catechol-O-methyltransferase inhibition on plasma homocysteine levels in levodopa-treated Parkinson's disease","volume":"133","author":"Kamiyama D","year":"2026","unstructured":"Kamiyama D, Nishikawa N, Iwaki H, et al.. Impact of catechol-O-methyltransferase inhibition on plasma homocysteine levels in levodopa-treated Parkinson's disease. J Neural Transm (Vienna). 2026, 133:1481-8. 10.1007\/s00702-026-03161-9","journal-title":"J Neural Transm (Vienna)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.64898\/2026.04.22.719490","article-title":"Brain B vitamin status and one-carbon metabolism gene polymorphisms are associated with cognitive impairment in Alzheimer's and Parkinson's disease [PREPRINT]","author":"Kaleck\u00fd K","year":"2026","unstructured":"Kaleck\u00fd K, Casta\u00f1eda-Gill J, Patel S, Bottiglieri T. Brain B vitamin status and one-carbon metabolism gene polymorphisms are associated with cognitive impairment in Alzheimer's and Parkinson's disease [PREPRINT]. bioRxiv. 2026, 10.64898\/2026.04.22.719490","journal-title":"bioRxiv"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2015.05.059","article-title":"Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease","volume":"25","author":"Chang FC","year":"2016","unstructured":"Chang FC, Kwan V, van der Poorten D, et al.. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. J Clin Neurosci. 2016, 25:41-5. 10.1016\/j.jocn.2015.05.059","journal-title":"J Clin Neurosci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12526","article-title":"Effect of levodopa-carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson's disease","volume":"4","author":"Standaert DG","year":"2017","unstructured":"Standaert DG, Rodriguez RL, Slevin JT, et al.. Effect of levodopa-carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson's disease. Mov Disord Clin Pract. 2017, 4:829-37. 10.1002\/mdc3.12526","journal-title":"Mov Disord Clin Pract"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2019.12.001","article-title":"A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: results from 6 phase 3\/3b open-label studies","volume":"2","author":"Boyd JT","year":"2020","unstructured":"Boyd JT, Zadikoff C, Benesh JA, et al.. A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: results from 6 phase 3\/3b open-label studies. Clin Park Relat Disord. 2020, 2:25-34. 10.1016\/j.prdoa.2019.12.001","journal-title":"Clin Park Relat Disord"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2408","article-title":"Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa\/carbidopa intestinal gel","volume":"11","author":"Pauls KA","year":"2021","unstructured":"Pauls KA, Toppila J, Koivu M, Eerola-Rautio J, Udd M, Pekkonen E. Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa\/carbidopa intestinal gel. Brain Behav. 2021, 11:e2408. 10.1002\/brb3.2408","journal-title":"Brain Behav"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27883","article-title":"Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease","volume":"34","author":"Morales-Brice\u00f1o H","year":"2019","unstructured":"Morales-Brice\u00f1o H, Mahant N, Ha AD, et al.. Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease. Mov Disord. 2019, 34:1747-8. 10.1002\/mds.27883","journal-title":"Mov Disord"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70093","article-title":"Levodopa-carbidopa intestinal gel in an outpatient setting: a 10-year experience","volume":"12","author":"Magliozzi A","year":"2025","unstructured":"Magliozzi A, Feugas N, Poon YY, et al.. Levodopa-carbidopa intestinal gel in an outpatient setting: a 10-year experience. Mov Disord Clin Pract. 2025, 12:1208-10. 10.1002\/mdc3.70093","journal-title":"Mov Disord Clin Pract"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13926","article-title":"Levodopa-entacapone-carbidopa intestinal gel treatment in advanced Parkinson's disease: a single-center study of 30 patients","volume":"11","author":"Viljaharju V","year":"2024","unstructured":"Viljaharju V, Mertsalmi T, Pauls KA, Koivu M, Eerola-Rautio J, Udd M, Pekkonen E. Levodopa-entacapone-carbidopa intestinal gel treatment in advanced Parkinson's disease: a single-center study of 30 patients. Mov Disord Clin Pract. 2024, 11:159-65. 10.1002\/mdc3.13926","journal-title":"Mov Disord Clin Pract"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2026.107528","article-title":"Seizures due to pyridoxine deficiency in a patient with advanced Parkinson's disease undergoing treatment with continuous enteral levodopa infusion","volume":"166","author":"Castro-Vilanova MD","year":"2026","unstructured":"Castro-Vilanova MD, Koukoulis-Fern\u00e1ndez A, Alv\u00e1rez-Garc\u00eda E. Seizures due to pyridoxine deficiency in a patient with advanced Parkinson's disease undergoing treatment with continuous enteral levodopa infusion. Med Clin (Barc). 2026, 166:107528. 10.1016\/j.medcli.2026.107528","journal-title":"Med Clin (Barc)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1177\/19418744251360306","article-title":"New onset medically refractory seizures in an adult with Parkinson's disease and vitamin B6 deficiency case report","volume":"16","author":"Nathan CL","year":"2026","unstructured":"Nathan CL, Ghandour D, May J, Bega D, Schuele S. New onset medically refractory seizures in an adult with Parkinson's disease and vitamin B6 deficiency case report. Neurohospitalist. 2026, 16:83-7. 10.1177\/19418744251360306","journal-title":"Neurohospitalist"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1159\/000525234","article-title":"Refractory seizures secondary to vitamin B6 deficiency in Parkinson disease: the role of carbidopa-levodopa","volume":"14","author":"Wise A","year":"2022","unstructured":"Wise A, Lemus HN, Fields M, Swan M, Bressman S. Refractory seizures secondary to vitamin B6 deficiency in Parkinson disease: the role of carbidopa-levodopa. Case Rep Neurol. 2022, 14:291-5. 10.1159\/000525234","journal-title":"Case Rep Neurol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvab262","article-title":"Severe hyperhomocysteinemia in a patient with Parkinson disease","volume":"68","author":"Bj\u00f8rke-Monsen AL","year":"2022","unstructured":"Bj\u00f8rke-Monsen AL, Bj\u00f8rk MH, Storstein A, Ueland PM, Tysnes OB. Severe hyperhomocysteinemia in a patient with Parkinson disease. Clin Chem. 2022, 68:396-401. 10.1093\/clinchem\/hvab262","journal-title":"Clin Chem"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrleng.2021.10.002","article-title":"Refractory status epilepticus due to vitamin B(6) deficit in a Parkinson's disease patient in treatment with levodopa\/carbidopa intestinal gel","volume":"37","author":"Baviera-Mu\u00f1oz R","year":"2022","unstructured":"Baviera-Mu\u00f1oz R, Buigues-Lafuente A, Campins-Romeu M, Garc\u00e9s-S\u00e1nchez M, Martinez-Torres I. Refractory status epilepticus due to vitamin B(6) deficit in a Parkinson's disease patient in treatment with levodopa\/carbidopa intestinal gel. Neurologia (Engl Ed). 2022, 37:608-9. 10.1016\/j.nrleng.2021.10.002","journal-title":"Neurologia (Engl Ed)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2023.53","article-title":"Oral levodopa, vitamin B6, and polyneuropathy: a case series","volume":"51","author":"D\u00e9ry C","year":"2024","unstructured":"D\u00e9ry C, Labrecque G, Bouchard M. Oral levodopa, vitamin B6, and polyneuropathy: a case series. Can J Neurol Sci. 2024, 51:472-3. 10.1017\/cjn.2023.53","journal-title":"Can J Neurol Sci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.12785","article-title":"Sensory neuropathy complicated with de novo diabetes mellitus during levodopa-carbidopa intestinal gel infusion in a patient with Parkinson's disease: a case report","volume":"12","author":"Ueno T","year":"2024","unstructured":"Ueno T, Baba M, Haga R, Arai A, Hattori N, Tomiyama M. Sensory neuropathy complicated with de novo diabetes mellitus during levodopa-carbidopa intestinal gel infusion in a patient with Parkinson's disease: a case report. Neurol Clin Neurosci. 2024, 12:195-7. 10.1111\/ncn3.12785","journal-title":"Neurol Clin Neurosci"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.08.007","article-title":"Guillain-Barre\/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa\/carbidopa treatment","volume":"20","author":"Galazky I","year":"2014","unstructured":"Galazky I, Schoof J, Stallforth S, Kupsch A, Heinze HJ, Kluge C. Guillain-Barre\/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa\/carbidopa treatment. Parkinsonism Relat Disord. 2014, 20:125-7. 10.1016\/j.parkreldis.2013.08.007","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521033-potential-vitamin-b6-depletion-during-carbidopalevodopa-therapy-in-parkinsons-disease-a-scoping-review-of-direct-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:33:23Z","timestamp":1786113203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521033-potential-vitamin-b6-depletion-during-carbidopalevodopa-therapy-in-parkinsons-disease-a-scoping-review-of-direct-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.114123","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}